Ticker

PHIL.MI

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in Phase II trial for the treatment of non-small cell lung cancer. It is also developing Dekavil (F8IL10), an anti-inflammatory product in Phase II trial for the treatment of chronic inflammatory disorders; Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12, which is in Phase I trial to treat advanced solid tumors; OncoFAP radio conjugates, a small molecule radiotracer with ultra high affinity for fibroblast activation protein in Phase I trial for diagnostic and therapeutic applications of metastatic solid tumors; OncoACP3, a small molecule radiotracer with ultra high-affinity for acid phosphatase 3 in Phase I trial for diagnostic and therapeutic applications for prostate cancer; OncoCAIX, a small molecule radiotracer in Phase 1 trial for the detection of Carbonic Anhydrase IX (CAIX) expressed in renal cell carcinoma and other hypoxic tumors; and OncoFAP-GlyPro-MMAE, a small molecule drug conjugate with ultra-high affinity for fibroblast activation protein in preclinical trial for the treatment of solid tumors. Philogen S.p.A. was founded in 1996 and is headquartered in Siena, Italy.